Clinical Trial Details
— Status: Withdrawn
Administrative data
NCT number |
NCT03267199 |
Other study ID # |
17100302 |
Secondary ID |
|
Status |
Withdrawn |
Phase |
|
First received |
|
Last updated |
|
Start date |
December 2020 |
Est. completion date |
August 2021 |
Study information
Verified date |
February 2023 |
Source |
Assiut University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
- The relationship between admission MPV, PDW, platelet function test and ST-segment
resolution in STEMI patients treated with either thrombolytic therapy or primary
percutaneous coronary intervention
- The relationship between admission MPV, PDW, platelet function test and high thrombus
burden & post-PCI Thrombolysis In Myocardial Infarction (TIMI) flow of infarct related
artery in STEMI patients treated with primary percutaneous coronary intervention
Description:
Reperfusion therapy as the main treatment strategy in patients with ST-segment elevation
myocardial infarction (STEMI) consists of either thrombolysis or primary percutaneous
coronary intervention (pPCI). Primary percutaneous coronary intervention is the preferred
therapy for STEMI; however, cardiac catheterization laboratories may not be widely available.
Early recanalization of the infarct related artery (IRA) by either thrombolytics or
percutaneous coronary intervention (PCI) is the main goal in the treatment of acute
myocardial infarction. But the eventual aim is to provide reperfusion at the tissue level as
well as in the infarct related artery .
Resolution of ST elevation has been shown as an agreeable marker that reflects both
epicardial and myocardial reperfusion . In addition, early and complete resolution of ST
-segment in the setting of acute myocardial infarction is associated with smaller infarct
size, greater ejection fraction and reduced morbidity and mortality .
Platelets play a critical role in the pathogenesis and prognosis of ACS . They secrete a
number of substances that are key mediators of coagulation, thrombosis and atherosclerosis.
High-volume platelets have a higher thrombotic potential than small platelets and have
concentrated granule contents that are of interest in the development of ACS pathogenesis .
Mean platelet volume (MPV) is the most commonly used measure of platelet size and correlates
with platelet activity. Platelet distribution width (PDW) is an index reflecting
heterogeneous platelet size, whereas the platelet-large cell ratio (P-LCR) is the proportion
of large platelets in blood circulation. Generally, higher MPV, PDW and P-LCR are correlated
with increased platelet size, although they tend to be overlooked in clinical applications.
In fact, these indices, particularly MPV and PDW, correlate with platelet functions.
Percutaneous coronary intervention (PCI) is an effective treatment for acute coronary
syndrome (ACS), including ST-elevation myocardial infarction (STEMI) and unstable angina.
Despite the efficacy of the technique, preprocedural high-thrombus burden (HTB) is a
predictor of procedural complications following primary PCI for STEMI. HTB can lead to poor
outcomes, including distal embolization, no-reflow, increased myocardial necrosis and
decreased left ventricular function.
Although MPV is associated with impaired angiographic reperfusion and poor clinical outcome
in patients with STEMI,little is known regarding the association between MPV levels and
infarct related artery patency in those patients.